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Background and purpose: The adenosine 2B (A2B) receptor is the predominant adenosine receptor expressed in the colon.
Acting through the A2B receptor, adenosine mediates chloride secretion, as well as fibronectin and interleukin (IL)-6 synthesis
and secretion in intestinal epithelial cells. A2B receptor mRNA and protein expression are increased during human and murine
colitis. However, the effect of the A2B receptor in the activation of the intestinal inflammatory response is not known. In this
study, we examined the effect of A2B receptor antagonism on murine colitis.
Experimental approach: Dextran sodium sulphate (DSS)-treated mice and piroxicam-treated IL-10
 /  mice were used as
animal models of colitis. The A2B receptor-selective antagonist, ATL-801, was given in the diet.
Key results: Mice fed ATL-801 along with DSS showed a significantly lower extent and severity of colitis than mice treated with
DSS alone, as shown by reduced clinical symptoms, histological scores, IL-6 levels and proliferation indices. The administration
of ATL-801 prevented weight loss, suppressed the inflammatory infiltrate into colonic mucosa and decreased epithelial
hyperplasia in piroxicam-treated IL-10
 /  mice. IL-6 and keratinocyte-derived chemokine (KC) concentrations in the
supernatants of colonic organ cultures from colitic mice were significantly reduced by ATL-801 administration.
Conclusions and implications: Taken together, these data demonstrate that the intestinal epithelial A2B receptor is an
important mediator of pro-inflammatory responses in the intestine and that A2B receptor blockade may be an effective
therapeutic strategy to treat inflammatory bowel disease.
British Journal of Pharmacology (2008) 155, 127–137; doi:10.1038/bjp.2008.227; published online 9 June 2008
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Abbreviations: A2B, adenosine 2B; DSS, dextran sodium sulphate; IBD, inflammatory bowel disease; IL, interleukin; KC,
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Introduction
Adenosine is a purine nucleoside that plays a key role in
nucleic acid, energy and protein metabolism. As an extra-
cellular autocoid, generated by the action of 50 nucleotidase
on adenosine 50 monophosphate, it is a powerful mediator of
cellular responses. Its levels increase under conditions of
cellular stress, hypoxia or inflammation. Adenosine exerts its
effects through one of the four known cell-surface G-protein-
coupled receptors: adenosine A1 (A1), adenosine A2A (A2A),
adenosine A2B (A2B) and adenosine A3 (A3) receptors
(Alexander et al., 2008). Of these four adenosine receptors,
the A2B receptor is the predominant adenosine receptor
expressed by colonic mucosa (Strohmeier et al., 1995).
Indeed, in human colonic epithelia it is the only adenosine
receptor expressed. It positively couples to adenylyl cyclase
and it signals through cAMP (Strohmeier et al., 1995). The
A2B receptor is expressed at both the apical and basolateral
surfaces of colonic epithelial cells. We recently demonstrated
that A2B receptor mRNA and protein expression are induced
in epithelial cells during human and murine colitis
(Kolachala et al., 2005a).
In the intestine, the A2B receptor mediates adenosine-
induced vectorial chloride secretion (Barrett, 1991;
Strohmeier et al., 1995) which, when upregulated, leads to
secretory diarrhoea. In addition, the A2B receptor mediates
the synthesis and secretion of interleukin (IL)-6 and
fibronectin through the activation of the cAMP/CREB (cAMP
response element-binding protein) signalling pathway. Inter-
estingly, both IL-6 and fibronectin secretion, mediated by
BJPOpen   
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et al., 2001). Studies in our laboratory and others have
demonstrated that adenosine-mediated IL-6 secretion
activates neutrophils (Sitaraman et al., 2001) and aids in
neutrophil-mediated bacterial killing (Nadeau et al., 2002).
Fibronectin released in the apical compartment significantly
enhances the adherence and invasion of Salmonella typhi-
murium into epithelial cells (Walia et al., 2004; Dorsey et al.,
2005).
The biological effects of adenosine in the intestine suggest
that the A2B receptor may be pro-inflammatory; hence, we
hypothesized that A2B receptor antagonists may have
therapeutic benefits in inflammatory diseases, such as
inflammatory bowel disease (IBD). To test this hypothesis,
we studied the effect of a newly developed, highly specific
inhibitor of the A2B receptor, ATL-801, (N-[5-(1-cyclopro-
pyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyri-
din-2-yl]-N-ethyl-nicotinamide; Wang et al., 2007) in the
development of colitis using two established models of
murine colitis (Cooper et al., 1993; Berg et al., 2002).
Materials and methods
Adenosine receptor-binding assay
Binding affinities of ATL-801 to adenosine receptors were
evaluated using receptor plasmids (A1,A 2A,A 2B and A3)
generated by PCR from human or mouse tissues and cloned
into pcDNA 3. 1. HEK293 cells were stably transfected using
lipofectin with selection in 1mgmL
 1 G418. Clones expres-
sing high numbers of receptors were carried in 0.5mgmL
 1
G418. For radioligand-binding assays, membranes were
prepared from transfected cells and the affinity of ATL-801
was determined by competition for radioligand binding.
Membranes were incubated at room temperature for 2h with
radioligands (A1 and A3:[
125I]N
6-4-amino-3-iodo-benzylade-
nosine (
125I-ABA); A2A:
125I4-(2-[7-amino-2-[2-furyl] [1,2,4]
triazolo[2,3-a] [1,3,5]triazin-5-yl-amino]ethyl) phenol (
125I-
ZM-241385); A2B:
125I3-(4-aminobenzyl)-8-phenyloxyace-
tate-1-propyl-xanthine (
125I-ABOPX) 7, concentrations of
ATL-801 ranging from 10
 10 to 10
 5 M and 1UmL
 1
adenosine deaminase, filtered over glass fiber filters,
and retained radioactivity counted in a g counter. Non-
specific binding was measured in the presence of 100mM
50-(N-ethylcarboxamido) adenosine (NECA). IC50 values
and inhibition constants (Ki values) were determined as
described by Linden (1982)
Experimental animals
The Animal Care Committee of the Emory University,
Atlanta, GA, approved all procedures performed on animals.
Age- and sex-matched 6-week-old C57BL/6 and IL-10
 / 
mice on C57BL/6 background were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). C57BL/6 mice were used
for experiments with dextran sodium sulphate (DSS). Mice
were maintained on a 12-h dark–light cycle and allowed free
access to powdered or pelleted diet and tap water under
conditions of controlled temperatures (25±21C).
Induction of DSS colitis
Colitis was induced in male C57BL/6 mice by oral admin-
istration of DSS (molecular wt. 50000; ICN Biomedicals,
Aurora, OH, USA) at 3% (wt/vol) in tap water ad libitum for 7
days. Age-matched male wild-type C57BL/6 mice receiving
tap water served as controls. Mice were observed daily and
evaluated for changes in body weight and development of
clinical symptoms. Mice were given ATL-801 10mgkg
 1 diet
(approximately 20mgday
 1 per mouse) during the adminis-
tration of DSS.
Piroxicam-induced colitis
IL-10
 /  mice spontaneously develop a chronic, T-cell-
mediated, transmural colitis that shares many features with
human Crohn’s disease. On the basis of this model, there
have been several clinical trials using IL-10 treatment for IBD
in human patients (Schreiber et al., 2000). However, due to
the inconsistency in the development of spontaneous colitis
in IL-10
 /  mice, Berg et al. (2002) have described rapid
development of colitis in IL-10
 /  mice treated with
piroxicam, a non-steroidal anti-inflammatory drug. Accord-
ingly, these mice were treated with piroxicam, 200mgkg
 1
diet, for 2 weeks to induce colitis. The diet containing
piroxicam was prepared fresh every 2 days as described (Berg
et al., 2002). Mice were given ATL-801 for a week prior to
treatment with piroxicam, and ATL-801 treatment was
continued during piroxicam administration. At 2 weeks after
the induction of colitis, mice were killed and colonic tissue
was removed for analysis.
Clinical score and histological scoring
Assessment of body weights, stool consistency and the
presence of occult/gross blood by a guaic test (Hemoccult
Sensa; Beckman Coulter, Fullerton, CA, USA) was performed
daily for each mouse. Colitis was quantified with a clinical
and histological score, as described by Cooper et al. (1993).
Clinical score was based on weight loss, stool consistency
and fecal blood (score range 0–12). Histological scoring was
performed based on three variables, extent of inflammatory
infiltrate, mucosal ulcers and severity of crypt damage (score
range 0–11) (Cooper et al., 1993). IL-10
 /  mouse colon
histological scoring (ranging from 0 to 4) was performed as
described by Berg et al. (2002) to assess intestinal lesions and
their severity.
Cytokine measurements
In the DSS model, pro-inflammatory cytokines were mea-
sured by real-time PCR. Total RNA was extracted from DSS-
treated, DSSþATL-801 and control colonic tissue using the
TRIzol reagent (Molecular Research Center Inc., Cincinnati,
OH, USA). After quantification, a reverse transcription
reaction was performed with 2mg of each sample and oligo-
dT primer, using the SuperScript First strand synthesis system
for reverse transcription-PCR (Invitrogen, Carlsbad, CA,
USA). The real-time iCycler sequence detection system
(Bio-Rad, Hercules, CA, USA) was used for the real-time
reverse transcription-PCR. Briefly, 3ng of reverse-transcribed
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Green Supermix (Bio-Rad) were amplified at 501C for 2min
and 951C for 10min, followed by 40 cycles of 951C for 15s
and 601C for 1min. The 36B4 expression levels were used as
a reference, and fold induction was calculated using a
standard curve. For graphical representation of quantitative
PCR data, raw cycle threshold values (Ct values) obtained for
treated mice were deducted from the Ct value obtained for
internal 36B4 transcript levels, using the Ct method as
follows: DDCT¼(Ct target Ct 36B4) treatment (Ct target Ct
36B4) no treatment, and the final data were derived from
2
 DDCT. Primers used were: IL-6 sense 50-ACAAGTCG
GAGGCTTAATTACACAT-30,a n t i s e n s e5 0-TTGCCATTGCAC
AACTCTTTTC-30; macrophage inhibitory protein (MIP)-2
sense 50-AGTGAACTGCGCTGTCAATGC-30, antisense 50-AG
GCAAACTTTTTGACCGCC-30.
In the IL-10
 /  model, pro-inflammatory cytokines were
measured by ELISA in organ cultures. Colon organ cultures
were prepared from IL-10
 /  mice with and without ATL-801
along with piroxicam. Colons were dissected from mice and
flushed with cold phosphate-buffered saline to remove fecal
matter. Each colon was cut into 1cm length and washed in
Hanks’ balanced salt solution with penicillin/streptomycin
and cultured in serum-free RPMI-1640 supplemented with
penicillin and streptomycin. Cultures were incubated at
371Ci n5 %C O 2. Supernatants were harvested after 24h,
centrifuged and stored at  801C before IL-6 and keratino-
cyte-derived chemokine (KC) levels were measured by ELISA
(Gewirtz et al., 2001). T84 cells were plated on plastic. After
reaching confluency, cells were treated with or without
ATL-801 (100mM) for 30min and then treated with flagellin
(100ngmL
 1) for 5h. IL-8 was measured in the supernatants
by ELISA (Gewirtz et al., 2001).
Myeloperoxidase assay
Neutrophil infiltration into colon was quantified by measur-
ing myeloperoxidase (MPO) activity as described previously
(Castaneda et al., 2005). One unit of MPO activity was
defined as the amount degrading 1mmol of peroxide in 1
minute at 251C. The results were expressed as absorbance
(per milligram protein).
Apoptosis and proliferation. Apoptotic cells were identified
by fluorescent double immunofluorescent staining using
caspase-3 and terminal deoxyuridine nick-end labelling
(TUNEL). After deparaffinization and hydration, paraffin
sections of colon were retrieved for antigens in a pressure
cooker with sodium citrate (pH 6.0, 10mM) for 10min. After
cooling, the sections were quenched in 3% H2O2 in
methanol and then blocked with normal goat serum.
Caspase-3 was detected with rabbit anti-cleaved caspase-3
IgG overnight at 41C followed by a labelled streptavidin–
biotin staining method consisting of successive application
of secondary antibody streptavidin, biotin horseradish
peroxidase and cyanine-3 tyramide (Srinivasan et al., 2005).
We performed TUNEL staining using the in situ cell death
detection kit as described by the manufacturer (Roche
Applied Science, Indianapolis, IN, USA). Nuclei were stained
with Hoechst 33258 to count total crypt cell number. The
apoptotic index was defined as number of caspase-3 and
TUNEL-positive cells per crypt. Immunohistochemical stain-
ing for Ki67 was carried out using Vectastain ABC kit (Vector
Laboratories Inc., Burlingame, CA, USA) according to the
manufacturer’s protocol. To perform the standard staining
procedure, tissue sections were deparaffinized and rehy-
drated. Paraffin sections of colon were retrieved for antigens
in a pressure cooker with sodium citrate (pH 6.0, 10mM) for
10min before the application of primary Ki67 antibody
(1:500 dilutions, incubated 41C overnight). Enzyme-conju-
gated secondary antibodies were applied and the specific
staining was visualized after the addition of the enzyme-
specific substrate. These tissues were counterstained by
haematoxylin. Proliferation index was defined as number
of Ki67-positive cells per crypt.
cAMP measurement
T84 cells were stimulated with adenosine (100mM)o r
forskolin (10mM) for 7min, with or without ATL-801
(100mM). Total cell lysates were processed in the presence
of isobutylmethyl xanthine (1mM) to inhibit phosphodies-
terases. cAMP levels were measured in whole-cell lysates
using a competitive cAMP immunoassay kit (Applied
Biosystems, Bedford, MA, USA) according to the manufac-
turer’s instructions. Luminescence was read with a Lumino-
scan Ascent plate reader (Thermo Labsystems, Needham
Heights, MA, USA).
Electrophysiological studies
Electrophysiological studies were performed as described
previously (Sugi et al., 2001; Kolachala et al., 2005b). Mice
were killed by CO2/hypothermia. The colon was removed
and opened along the mesenteric border. The colon was then
stripped of its external muscle by blunt dissection. A
segment of mucosa from the distal colon was used for
Ussing chamber studies. After attaining a sustained baseline
Isc, mucosal layers were stimulated with adenosine (100mM)
and forskolin (10mM). Antagonist was added to both bathing
solutions before stimulating with adenosine.
Statistical analysis
The data are presented as mean±s.e. Statistical analysis was
conducted using Student’s t-test where Po0.05 was consid-
ered significant. In experiments wherein multiple group
comparison was involved, we used ANOVA.
Reagents
Adenosine (Research Biochemicals Int., Natick, MA, USA), 50-
(N-ethylcarboxamido) adenosine and piroxicam (Sigma
Aldrich, St Louis, MO, USA), isobutylmethyl xanthine
(Biomol Research Laboratories Inc., Plymouth Meeting, PA),
cAMP Screen Kit (Applied Biosystems), DSS (MP Biomedicals
Inc., Aurora, OH, USA), IL-6 and KC Duoset ELISA kit (R&D
Systems Inc., Minneapolis, MN, USA); ATL-801, the A2B
receptor-specific antagonist was a gift from Adenosine
Therapeutics LLC. The radioiodinated radioligands were
synthesized from non-radioactive precursors and carrier-free
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containing the ATL-801 inhibitor was obtained from Harlan
Tekad Research Diets (Madison, WI, USA). Antibodies Ki67
(Novocastra, Newcastle upon Tyne, UK), cleaved caspase-3
(Cell Signaling, Denvers, MA, USA), Vectastain immuno-
histochemistry kit (Vector Laboratories Inc.), TUNEL assay
kit (Roche Applied Science). T84 cells are a colonic epithelial
cell line, maintained in our laboratory.
Results
ATL-801 binds to the adenosine receptor
ATL-801 displayed high selectivity for the murine A2B
receptor (Ki¼187±96.3nM, n¼3) and human A2B receptor
(Ki¼19.32±2.2nM, n¼4) compared with its affinity to the
murine A1 receptor (Ki¼5162±610nM, n¼4) and the A2A
receptor (Ki¼3506±869nM 15% inhibition at 10mm, n¼3).
Radioligand binding to the mouse A3 receptor was inhibited
by only 10% at 10mM (Table 1). Concentration–response
curves of competitive binding assays, plotted as percent
bound (B/B0) against the log concentration of ATL-801,
demonstrated that ATL-801 has high affinity and selectivity
for the A2B receptor (Figure 1).
A2B receptor antagonism attenuates DSS-induced colitis
To investigate whether the A2B receptor plays a role in the
pathogenesis of intestinal inflammation, we used the DSS
model of colitis. The mice were divided into four groups: (i)
DSS alone, (ii) ATL-801 (10mgkg
 1)þDSS, (iii) water alone
and (iv) ATL-801þwater. The latter two groups served as
control groups. The mice were assessed for the clinical signs
of colitis (weight change, stool consistency and occult blood)
(Cooper et al., 1993). All of the mice exposed to DSS alone
developed clinical signs of colitis between days 5 and 6. As
shown in Figure 2a, the mice receiving DSS alone had a
clinical disease activity score of 9.4±1.1. These mice had
significant weight loss (5.9±0.6%), frank blood in their stool
(clinical score of 4) and diarrhoea. In contrast, mice given
DSS and ATL-801 showed a significantly lower clinical score
(Po0.003; Figure 2a); some mice that received DSSþATL-
801 demonstrated occult blood loss, whereas others had no
blood in their stool (clinical score of 0–1). Notably, mice
given ATL-801 with DSS had solid stools, in contrast to DSS-
fed mice, which had watery diarrhoea. The colons of mice
fed ATL-801 and DSS showed solid stool pellets, which is
reflected in their colon weight (0.48±0.03g), whereas the
DSS-fed mice had no stool in their colons (0.26±0.03g,
Po0.03, n¼5).
In the next set of experiments, we tested the therapeutic
efficacy of ATL-801 in the recovery (healing) phase of DSS-
induced colitis. Colitis was induced by the administration of
DSS in the drinking water for 7 days (colitic phase), after
which the mice were switched to plain drinking water for 7
additional days (recovery phase). One group of mice was
given a diet containing ATL-801 that was started during the
recovery phase, whereas another group of mice continued on
the diet without ATL-801. As shown in Figure 2b, mice given
DSS and not receiving ATL-801 continued to lose weight
during the recovery phase. In contrast, mice that received
ATL-801 did not lose body weight and showed a trend
towards recovery of their body weight. Taken together, these
data demonstrate that mice were not only protected from
DSS-induced colitis but also recovered faster when A2B
receptor signalling and function was inhibited.
As demonstrated by Okayasu et al. (1990), reduction of the
colon length, which is used as a parameter of inflammation,
correlated with the clinical data. Mice that received DSS
alone had a 30% shorter colon length at the end of the
experimental period (7 days of DSS) (4.5±0.26cm) com-
pared with mice given water (6.5±0.18cm, Po0.0001). ATL-
801 prevented the reduction in colon length induced by DSS
(6.04±0.16cm DSSþATL-801, Po0.001 compared with DSS
alone).
DSS-induced colitis is characterized by the presence of
inflammation of the colon, which is manifested by crypt
destruction, mucosal damage, epithelial erosions and infil-
tration of inflammatory cells into the mucosal tissue. Tissues
collected from mice exposed to DSS were examined histolo-
gically and compared with those that received DSSþATL-
801. Histological scoring was performed without the
Table 1 Affinities of ATL-801 for a range of human and mouse adenosine receptors
hA1 Ki
(nM)
hA2A low Ki
(nM)
hA2B Ki
(nM)
hA3 Ki
(nM)
Mouse A1 Ki
(nM)
Mouse A2A Ki
(nM)
Mouse A2B Ki
(nM)
Mouse A3 Ki
(nM)
4983±2661
n¼7
662.7±90.9
n¼6
19.32±2.2
n¼4
6314±1828
n¼6
5162±610
n¼4
15% (3506±869) inhibition
at 10mm n¼3
187±96.3
n¼3
10% inhibition at
10mm n¼3
Affinity values (as Ki) were obtained using HEK293 cells, stably transfected with the receptors shown (see Materials and methods for details).
Figure 1 ATL-801 has high affinity and selectivity for the A2B
receptor. HEK293 cells were stably transfected with A1,A 2A,A 2B and
A3 plasmids. Radioligand-binding assays were performed using ATL-
801, as described in the Materials and methods section. Data are
presented as percent bound (B/B0) against the log concentration of
adenosine receptor antagonist.
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(Cooper et al., 1993). The histological data corroborated
the clinical score and confirmed the protective role of ATL-
801 against the development of colitis. As shown in Table 2
and Figure 3a, DSS-treated mice exhibited obvious signs of
colon inflammation and tissue destruction. These mice had
extensive crypt damage, epithelial erosion/ulceration, crypt
abscess formation and infiltration of inflammatory cells into
the lamina propria and muscularis mucosa of colonic
sections (Table 2 and Figure 3a). In contrast, histological
analysis of the sections from mice fed ATL-801 and DSS
revealed significantly reduced histological inflammation,
and these mice appeared to be protected from DSS-associated
mucosal injury, having fewer inflammatory infiltrates and
ulcerations (Figure 3a). Overall, a lower histological score
was observed in mice given DSSþATL-801, compared with
the score in the DSS group (Po0.05; Table 2). Histological
signs of inflammation were not detected in the control
groups that received water or waterþATL-801.
To confirm the histological findings with respect to
granulocyte accumulation, we measured the activity of
MPO in the colonic tissue. MPO is an enzyme specific to
granulocyte lysosomes, and, therefore, it directly correlates
with the number of neutrophils. Mice fed with DSS alone
had significantly increased MPO activity (twofold, Po0.03)
compared with mice given DSSþ ATL-801 (Figure 3b).
A2B receptor antagonism suppresses pro-inflammatory cytokines
associated with DSS-induced colitis
As the DSS-induced inflammatory response is associated with
the production of pro-inflammatory cytokines, such as IL-6,
we measured IL-6 mRNA levels in the colonic mucosal tissue
of DSS-treated mice and compared them with mice that
received DSS along with the antagonist. As shown in
Figure 4a, mice treated with ATL-801 showed significantly
lower levels of the mRNA for IL-6, compared with mice that
received DSS alone (Po0.01). Similarly, as shown in
Figure 4b, levels of the mRNA for MIP-2 (a chemokine
secreted by macrophages and epithelial cells) were signifi-
cantly lower in the ATL-801-treated group (Po0.02) com-
pared with mice that received DSS alone. Taken together,
these data demonstrate that ATL-801 attenuated not only
the clinical characteristics but also the histological features
and inflammatory markers associated with DSS-induced
colitis.
A2B receptor antagonism reverses the effect of DSS colitis-induced
changes in epithelial cell proliferation and apoptosis
Next, we examined whether blockade of the A2B receptor
affected epithelial cell survival in colitic mice. Epithelial cell
proliferation was assessed by determining the number of
cells that were positive for Ki67, and apoptosis was assessed
with caspase-3 and TUNEL staining. As shown in Figure 5a,
the proliferation index represented by the percent of Ki67-
positive cells per crypt was significantly decreased in DSS-
treated mice compared with DSSþATL-801-treated mice
(control vs DSS Po0.001, DSS vs DSSþATL-801, Po0.001,
n¼5). In addition, ATL-801 significantly inhibited the
apoptosis associated with DSS-induced colitis. As shown in
Figure 5b, mice treated with DSS showed an increase in
apoptotic cells per crypt (Po0.01).
A2B receptor antagonism inhibits colitis in IL-10
 /  mice
We next determined the effects of ATL-801 in the develop-
ment of colitis in the IL-10
 /  piroxicam model of colitis.
Table 2 Histological assessment of colitis in mice treated with or
without ATL-801 after ingestion of 3% DSS in drinking water for 6 days
Parameters Water DSS DSSþATL 10mgkg
 1
Crypt damage 0 2.8±1.5 1.9±0.6
Inflammation 0.4±0.2 3.7±0.2 1.2±0.2
Ulceration 0 2.6±0.6 1.0±1.0
Total lesion score 0.4±0.2 9.1±2.3 4.1±1.8*
Abbreviation: DSS, dextran sodium sulphate. *Po0.05.
Figure 2 A2B receptor antagonism attenuates dextran sodium sulphate (DSS)-induced colitis. Mice were weighed and randomized into four
groups: (i) DSS alone (3%), (ii) DSSþATL-801, (iii) water and (iv) ATL-801 alone (groups three and four served as controls; data from group
three are shown here, which was similar to ATL-801 alone). Mice were killed after 7 days of ingesting DSS in drinking water. (a) Disease severity
was assessed as described in the Materials and methods section. The data are presented as clinical scores. (b) Percent change in body weight in
mice given DSS or DSSþATL-801. Results are expressed as mean±s.e., n¼5. *Po0.003.
Adenosine A2B receptor blockade improves colitis
VL Kolachala et al 131
British Journal of Pharmacology (2008) 155 127–137IL-10
 /  mice were treated with piroxicam±ATL-801 in their
diet, as described in the Materials and methods section. The
mice were killed at the end of 4 weeks, colonic tissues were
analysed and histological scoring (ranging from 0 to 4) was
performed to assess intestinal lesions and their severity (Berg
et al., 2002). The IL-10
 /  mice receiving piroxicam showed
significant weight loss, whereas IL-10
 /  mice that received
piroxicamþATL-801 maintained their body weight
(Figure 6a). Furthermore, marked immune cell infiltrates
were found in the mucosa and submucosa. Epithelial
Figure 3 A2B receptor antagonism inhibits inflammation associated with dextran sodium sulphate (DSS) ingestion. Mice were weighed and
randomized into four groups: (i) DSS alone (3%), (ii) DSSþATL-801, (iii) water and (iv) ATL-801 alone (groups three and four served as
controls; data from group three are shown here, which was similar to ATL-801 alone). Mice were killed after 7 days of ingesting DSS in drinking
water. (a) Colons were fixed in formalin, paraffin-embedded, sectioned and stained with haematoxylin and eosin. Representative sections of
colons are shown. Control (upper panels), DSS alone (middle panels) and DSSþATL-801 (bottom panels), n¼5. (b) Colons were snap frozen
in liquid nitrogen, and myeloperoxidase was measured as an index of neutrophil infiltration into the injured tissue, as described in the Materials
and methods section. Each bar represents mean±s.e. n¼5 animals per group, *Po0.038.
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(Figure 6b, upper panel). However, IL-10
 /  mice treated
with ATL-801 showed reduced inflammatory infiltrate as
well as reduced epithelial hyperplasia (Figure 6b, lower
panel). The mean histological score was significantly higher
in IL-10
 /  mice treated with piroxicam (2.8±1.0) compared
with the ATL-801-treated groups, which showed a histologi-
cal score of 1.3±0.3 (Po0.009). The IL-10
 /  mice treated
with ATL-801 alone showed normal histology (data not
shown). Further, the IL-10
 /  mice that received piroxicam
showed significantly reduced colon length (7.0±0.25cm)
compared with the IL-10
 /  mice that received ATL-
801þpiroxicam (8.4±0.23cm; Po0.008). Taken together,
these data suggest that inhibition of the A2B receptor reduced
the extent and severity of colitis in the IL-10
 /  mice/
piroxicam model.
A2B receptor antagonism suppresses the synthesis of
pro-inflammatory cytokines induced by piroxicam in IL-10
 /  mice
To determine the effect of A2B receptor inhibition on pro-
inflammatory cytokine synthesis, we obtained colonic tissue
from IL-10
 /  mice treated with piroxicam, with or without
ATL-801. IL-6 and KC levels were measured in the colon
culture supernatant, as described in the Materials and
methods section. IL-6 levels were upregulated in colon
cultures of IL-10
 /  mice treated with piroxicam alone,
compared with the piroxicamþATL-801-treated mice
(Po0.006) and untreated mice (Figure 7a). A similar inhibi-
tion of KC secretion was seen in tissue from mice treated
with piroxicamþATL-801 compared with tissue from mice
given piroxicam alone (Figure 7b). ATL-801, alone, had no
effect on IL-6 or KC levels (data not shown).
A2B receptor antagonism inhibits proliferation and enhances
apoptosis in IL-10
 /  mice with piroxicam-induced colitis
We further examined the effect of ATL-801 on epithelial cell
survival and apoptosis in IL-10
 /  mice treated with
piroxicam. Epithelial cell proliferation was assessed by
determining the number of cells staining positive for
Ki67, whereas apoptosis was assessed by caspase-3 and
TUNEL staining. As shown in Figure 8a, the proliferation
index, represented by the number of Ki67-positive cells
Figure 4 A2B receptor antagonism decreased levels of mRNA for cytokines in colitis. Total RNA from colonic mucosal strips was isolated,
reverse transcribed and subjected to real-time PCR analysis for IL-6 or macrophage inhibitory protein (MIP)-2 mRNA, as described in the
Materials and methods section. (a) Normalized IL-6 mRNA is represented as fold increase over control mice, n¼5, Po0.01. (b) Normalized
MIP-2 mRNA is represented as fold increase over control mice, n¼5, *Po0.002.
Figure 5 A2B receptor antagonism reversed the effect of epithelial proliferation and apoptosis in colons from mice with DSS-induced colitis.
Paraffin-embedded sections were stained for Ki67 or caspase-3 and TUNEL as described in the Materials and methods section. (a) Proliferation
index (percent Ki67-positive cells per crypt). (b) Apoptotic index (number of caspase-3- and TUNEL-positive cells per crypt). Data represent
averages of a total of 30 crypts per mouse, three mice per group, *Po0.001.
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 / 
mice that received piroxicam compared with the pirox-
icamþATL-801-treated mice (Po0.001, n¼4). In addition,
the IL-10
 /  mice treated with piroxicamþATL-801 showed
an increased apoptotic index (number of TUNEL- and
caspase-3-positive cells per crypt) compared with the
IL-10
 /  mice treated with piroxicam alone (Figure 8b).
These data are consistent with the inhibition of hyperplasia
that is characteristic of colitis associated with piroxicam-
treated IL-10
 /  mice.
The A2B receptor antagonist, ATL-801, inhibits
adenosine-mediated cAMP levels and short circuit current (Isc)
To see the functional aspects of A2B receptor inhibition, T84
colonic epithelial cells were treated with adenosine
Figure 6 A2B receptor antagonism inhibits colitis in IL-10
 /  mice. IL-10
 /  mice were weighed and randomized into four groups: untreated,
IL-10
 /  mice that received piroxicam alone (200mgkg
 1 diet), IL-10
 /  mice that received piroxicamþATL-801 (10mgkg
 1) and IL-10
 / 
mice that received ATL-801 alone (n¼5 per group). (a) Body weight change from baseline (grams), *Po0.05 (b) Colons were fixed in
formalin, paraffin-embedded, sectioned and stained with haematoxylin and eosin. Representative sections of colons from IL-10
 /  mice that
received piroxicam alone (top panel) or piroxicamþATL-801 (bottom panel) are shown (magnification  20).
Figure 7 The A2B receptor antagonist suppressed the production of pro-inflammatory cytokines. Colonic tissue culture supernatants,
obtained from IL-10
 /  mice treated with piroxicam, with or without ATL-801 (n¼5 per group), were processed for IL-6 (a) and KC (b)
secretion, as described in the Materials and methods section, *Po0.006.
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Figure 9a, ATL-801 significantly inhibited adenosine-
mediated changes in cAMP levels (Po0.002, n¼6;
Figure 9a). To determine the effect of ATL-801 on adeno-
sine-induced short circuit currents (Isc) in vivo, mucosal strips
from murine colons were placed in Ussing chambers and the
baseline Isc was measured. As shown in Figure 9b, stimula-
tion of the mouse colonic mucosa with adenosine (100mM)
showed a maximum DIsc and addition of ATL-801 (100mM)
virtually abolished this adenosine-induced Isc (Po0.004,
n¼3). However, as shown in Figure 9b, ATL-801 did not
affect forskolin (a direct activator of adenylyl cyclase)-
mediated Isc. Taken together, these data demonstrate that
ATL-801 is a potent inhibitor of adenosine-mediated cAMP
response and Isc. Furthermore, these data demonstrate that
the ATL-801 effect is specific to adenosine-induced Isc and
does not affect other cAMP-dependent Isc responses.
Discussion
In this study, we report that a selective A2B receptor
antagonist, ATL-801, ameliorates experimental colitis in
two mouse models that represent both acute and chronic
forms of gut inflammation. In the first model, colitis was
induced by the oral administration of DSS. ATL-801
protected these mice from DSS-induced colitis and reduced
inflammatory cell infiltration, focal crypt damage, epithelial
injury and ulceration. One of the findings was that mice
with DSS-induced colitis and treated with ATL-8801 showed
a marked reduction in diarrhoea, as demonstrated by solid
stool pellets and increased stool weight, compared with mice
ingesting with DSS alone. This result is consistent with a
known effect of adenosine in mediating cAMP-dependent
chloride secretion and secretory diarrhoea (Li et al., 2005).
Although the A2B receptor has been shown to mediate
Figure 8 The A2B receptor antagonist suppressed epithelial proliferation and induced apoptosis in piroxicam-induced colitis. Paraffin-
embedded colonic sections from IL-10
 /  mice treated with piroxicam, with or without ATL-801, were processed for Ki67 analysis (a)o r
caspase-3 and TUNEL staining (b) as described in the Materials and methods section. Data represent average proliferation and apoptotic
indices, respectively, from a total of 30 crypts per section, from three independent mice, *Po0.001.
Figure 9 The A2B receptor antagonist, ATL-801, inhibited adenosine-induced cAMP levels and short circuit current (Isc). (a) Monolayers of T84
cells were grown on snap wells and mounted in an Ussing chamber. The cells were stimulated with adenosine (100mM) after pretreatment
with or without ATL-801. cAMP levels were measured as described in the Materials and methods section. Data are represented as fold increase
over control, ATL-801þadenosine and adenosine alone Po0.0025, n¼3. (b) Colonic mucosal strips from the distal colon were mounted in an
Ussing chamber. The increase in Isc was determined as described in the Materials and methods section. After obtaining a baseline Isc, the
mucosa was stimulated with adenosine (100mM) or forskolin (FSK; 10mM). In addition, colonic mucosal strips were pretreated with ATL-801
(100mM), 5min before stimulating with adenosine or FSK (10mM). Data represent DIsc (ATL-801þadenosine) vs adenosine alone, *Po0.004,
n¼3.
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first demonstration of an effect of the A2B receptor on
diarrhoea in vivo. diarrhoea associated with intestinal
inflammation is multifactorial. The inhibition of adeno-
sine-induced chloride secretion by ATL-801 in colonic
mucosal strips ex vivo, in conjunction with the inhibition
of colitis-associated diarrhoea by ATL-801, suggests that
inhibition of chloride secretion is a possible mechanism by
which ATL-801 reduced diarrhoea in the DSS-induced colitis
model.
In addition to the effect of ATL-801 on diarrhoea,
inflammatory infiltration was reduced in both DSS and
IL-10
 /  mouse models of colitis. In the DSS model, which
is characterized by neutrophil infiltration, crypt injury and
ulcers, ATL-801 reduced the extent of neutrophil infiltration,
as assessed by histology and the MPO assay. There was
significantly less ulceration and crypt damage after ATL-801
treatment, and this effect was dose dependent. Similarly,
ATL-801 protected animals against the chronic inflamma-
tory infiltrate and epithelial hyperplasia that characterized
colitis in IL-10
 /  mice. Further, ATL-801 reversed changes in
epithelial cell survival associated with DSS-induced or
piroxicam/IL-10
 / -associated colitis. DSS-induced colitis
has been reported to be associated with an inhibition of cell
proliferation and increased apoptosis (Vetuschi et al., 2002),
whereas piroxicam-induced colitis in IL-10
 /  mice has been
shown to be associated with epithelial hyperplasia. Finally,
the protective effect of ATL-801 on colitis was reflected by
reduced pro-inflammatory cytokine secretion from colons of
colitic mice.
The A2B receptor mediates biological responses in several
tissues and, depending on the cell type or tissue, the A2B
receptor mediates pro- or anti-inflammatory effects. For
example, in the lung, the A2B receptor mediates broncho-
constriction in asthma by mediating pro-inflammatory and
pro-fibrogenic effects. A2B receptor antagonists are highly
effective at reducing pulmonary injury and inflammation
(Sun et al., 2006). In contrast, the A2B receptor has been
shown to mediate a protective effect against endotoxin-
induced sepsis, by regulating inflammation and vascular
adhesion (Yang et al., 2006) and against cardiac fibrosis, by
modulating cardiac fibroblastic proliferation (Chen et al.,
2004). In fibroblasts and endothelial cells, the A2B receptor
has been shown to inhibit tumour necrosis factor alpha
(TNF-a) synthesis and signalling (Zhang et al., 2005; Kreckler
et al., 2006). In addition, the A2B receptor can act in an anti-
inflammatory manner; it modulates macrophage function
by inhibiting the production of TNF-a and IL-1b, whereas
stimulating IL-10 and inhibiting cell proliferation (Xaus
et al., 1999; Nemeth et al., 2005; Sipka et al., 2005; Kreckler
et al., 2006). Our results suggest that during colitis, inhibi-
tion of the A2B receptor may offer a regulatory signal that
suppresses the pro-inflammatory effects, thereby ameliorat-
ing tissue damage.
Both immune cells and colonic epithelial cells express A2B
receptors. In colonic epithelial cells, the A2B receptor is the
only adenosine receptor expressed, whereas immune cells
express multiple adenosine receptor subtypes (Cronstein
et al., 1990; Salmon and Cronstein, 1990). With the
combination of pharmacological data using selective ligands
as well as gene knockout mice, important advances have
been made towards an explanation of the role of adenosine
receptors in IBD. Recent studies suggest a protective role for
the A2A receptor subtype (Odashima et al., 2005; Naganuma
et al., 2006) in some models of murine colitis. The protective
effect of the A2A receptor on the development of colitis has
been shown to be mediated by A2A receptors expressed in T
cells (Naganuma et al., 2006). A3 receptors have been
demonstrated to mediate a pro-inflammatory effect in two
models of colitis, similar to our observations with A2B
receptor antagonism (Mabley et al., 2003). Whether or not
the protective effect of A2B receptor antagonism is mediated
by epithelial cells, immune cells or both is unclear at this
time. We have previously demonstrated that A2B receptor
expression is upregulated in epithelial cells in animal models
(DSS) as well as in human IBD (Kolachala et al., 2005a). We
further demonstrated that the increase in A2B receptor
expression is mediated by TNF-a (Kolachala et al., 2005a).
Moreover, adenosine levels are highly upregulated in
luminal fluid during active flare-ups of IBD, and adenosine
induces recruitment of the A2B receptor, preferentially, to the
apical membrane. In addition, ATL-801 is a highly polar
compound whose systemic bioavailability is restricted by its
limited absorption through the gastrointestinal tract (J
Linden, unpublished data). Given these effects of adenosine
and the limited absorption of ATL-801, it is likely that the
inflammatory response and its inhibition by ATL-801 are, at
least in part, mediated by the colonic epithelial A2B receptor.
However, further studies are required to delineate the role of
mucosal vs immune cell A2B receptors in the development of
colitis.
In conclusion, the data presented in this study demon-
strate important anti-inflammatory effects of the selective
A2B receptor antagonist, ATL-801. Thus, modulation of A2B
receptor-mediated signalling through selective A2B receptor
antagonism could provide a firm basis for developing
adenosine A2B receptor antagonists as a new therapeutic
approach for patients with IBD.
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